Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate plasma and target site concentrations derived from their established human pharmacokinetics

Usman Arshad¹, Henry Pertinez¹, Helen Box¹, Lee Tatham¹, Rajith KR Rajoli¹, Paul Curley¹, Megan Neary¹, Joanne Sharp¹, Neill J Liptrott¹, Anthony Valentijn¹, Christopher David¹, Steve P Rannard², Paul O'Neill², Ghaith Aljayyousi³, Shaun Pennington³, Stephen A Ward³, David J Back¹, Saye H Khoo¹, Patrick G Bray⁴, Giancarlo Biagini³, Andrew Owen¹.

¹Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, L7 3NY, UK

²Department of Chemistry, University of Liverpool, Liverpool, L69 3BX, UK

³Centre for Drugs and Diagnostics. Liverpool School of Tropical Medicine, Liverpool L3 5QA, UK

⁴Pat Bray Electrical, 260D Orrell Road, Orrell, Wigan, WN5 8QZ, UK

Author for correspondence:

Professor Andrew Owen

Department of Molecular and Clinical Pharmacology

Materials Innovation Factory

University of Liverpool

51 Oxford Street,

Liverpool L7 3NY

United Kingdom

aowen@liverpool.ac.uk

Abstract

There is a rapidly expanding literature on the *in vitro* antiviral activity of drugs that may be repurposed for therapy or chemoprophylaxis against SARS-CoV-2. However, this has not been accompanied by a comprehensive evaluation of the ability of these drugs to achieve target plasma and lung concentrations following approved dosing in humans. Moreover, most publications have focussed on 50% maximum effective concentrations (EC_{50}), which may be an insufficiently robust indicator of antiviral activity because of marked differences in the slope of the concentration-response curve between drugs. Accordingly, *in vitro* anti-SARS-CoV-2 activity data was digitised from all available publications up to 13th April 2020 and used to recalculate an EC_{90} value for each drug. EC_{90} values were then expressed as a ratio to the achievable maximum plasma concentrations (C_{max}) reported for each drug after administration of the approved dose to humans (C_{max}/EC_{90} ratio). Only 14 of the 56 analysed drugs achieved a C_{max}/EC_{90} ratio above 1 meaning that plasma C_{max} concentrations exceeded those necessary to inhibit 90% of SARS-CoV-2 replication. A more in-depth assessment of the putative agents tested demonstrated that only nitazoxanide, nelfinavir, tipranavir (boosted with ritonavir) and sulfadoxine achieved plasma concentrations above their reported anti-SARS-CoV-2 activity across their entire approved dosing interval at their approved human dose. For all drugs reported, the unbound lung to plasma tissue partition coefficient ($K_p U_{lung}$) was also simulated and used along with reported C_{max} and fraction unbound in plasma to derive a lung C_{max}/EC_{50} as a better indicator of potential human efficacy (lung C_{max}/EC_{90} ratio was also calculable for a limited number of drugs). Using this parameter hydroxychloroquine, chloroquine, mefloquine, atazanavir (boosted with ritonavir), tipranavir (boosted with ritonavir), ivermectin, azithromycin and lopinavir (boosted with ritonavir) were all predicted to achieve lung concentrations over 10-fold higher than their reported EC_{50} . This analysis was not possible for nelfinavir because insufficient data were available to calculate $K_p U_{lung}$ but nitazoxanide and sulfadoxine were also predicted to exceed their reported EC_{50} by 3.1- and 1.5-fold in lung, respectively. The antiviral activity data reported to date have been acquired under different laboratory conditions across multiple groups, applying variable levels of stringency. However, this analysis may be used to select potential candidates for further clinical testing, while deprioritising compounds which are unlikely to attain target concentrations for antiviral activity. Future studies should focus on EC_{90} values and discuss findings in the context of achievable exposures in humans, especially within target compartments such as the lung, in order to maximise the potential for success of proposed human clinical trials.

Introduction

Coronavirus 2019 (COVID-19) is a respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Fever, a persistent cough and respiratory symptoms are common, with some patients reporting vomiting, nausea, abdominal pains and diarrhoea [1]. To date, no specific treatment is available, and this has resulted in significant morbidity and mortality globally. According to the International Clinical Trials Registry Platform search portal, 927 clinical trials for COVID-19 have been registered [2]. This rapidly expanding pandemic warrants the urgent development of strategies, particularly to protect people at high risk of infection. Repurposing currently available drugs that have been utilised clinically with a known safety profile, is the quickest way to address this serious unmet clinical need. Antiviral drugs are urgently required for treatment of patients with mild/moderate disease to prevent the worsening of symptoms and reduce the burden upon healthcare systems. However, a different approach is likely to be needed for patients that are already in a critical state, due to the immune dysregulation which is so apparent in severe cases [3].

Previous investigations have shown that the entry by SARS-CoV occurs via the angiotensin converting enzyme 2 (ACE2) receptor [4]. A study on normal lung tissue showed that 83% of ACE2-expressing cells were alveolar epithelial type II cells [5], highlighting the lungs as the primary target organ that facilitate viral invasion and replication. Furthermore, the ACE2 receptor is also highly expressed in gastrointestinal epithelial cells, with SARS-CoV-2 RNA observed to be present in stool specimens of patients during infection [1, 6]. A recent retrospective analysis of 85 patients with laboratory confirmed COVID-19 also indicated that SARS-CoV-2 infects human kidney tubules and induces acute tubular damage in some patients [7]. Furthermore, 2–11% of patients with COVID-19 exhibit liver comorbidities [8]. Of note is an observation of SARS and Middle East respiratory syndrome (MERS) having a tropism to the gastrointestinal tract [9] and causing liver impairments in addition to respiratory disease. The genomic similarity between SARS-CoV-2 and SARS-CoV (79.6% sequence identity) would imply that the current virus would act in a similar manner and be present within the body systemically [10-12]. Therefore, treatment options that provide therapeutic concentrations of drug(s) within the systemic circulation and other affected organs are likely to be required.

In the absence of a vaccine, antiviral drugs could also be deployed as chemoprophylaxis to protect against infection and would present an essential tool for protecting healthcare staff and other key workers, as well as household contacts of those already infected. For chemoprevention drugs will need to penetrate into the multiple sites where SARS-CoV-2 infection occurs, and do so in sufficient concentrations to inhibit viral replication [13]. This may include the mucous membranes present in the nasal cavity and throat, the ocular surface, tears and the upper respiratory tract/lungs [14, 15].

However, therapeutic concentrations may not be needed in the systemic circulation for chemoprophylaxis, but this is yet to be determined. Although difficult and scarcely studied, work in animals has shown that the size of the inoculum of other respiratory viruses such as influenza is associated with the severity of the resultant disease [16, 17]. Reports with SARS-CoV-2 indicate that higher viral loads are indicative of poorer prognosis and correlate with the severity of symptoms, with viral load in severe cases reported to be 60 times higher than that of mild cases [18, 19]. In light of this, even if a chemoprophylactic drug reduced inoculum size without completely blocking transmission, major benefits for morbidity and mortality may still be achievable.

Many ongoing global research efforts are focused on screening the activity of existing compounds *in vitro* in order to identify candidates to repurpose for SARS-CoV-2. However, current data have not yet been systematically analysed in the context of the plasma and target site exposures that are achievable after administration of the approved doses to humans. The purpose of this work was to evaluate the existing *in vitro* anti-SARS-CoV-2 data to determine and prioritise drugs capable of reaching antiviral concentrations within the blood plasma. An accepted physiologically-based pharmacokinetic (PBPK) equation was also used to predict the expected concentration in lung, in order to assess the potential of these drugs for therapy in this key disease site and the potential for chemoprevention.

Methods

Candidate Analysis

To identify compounds and their relevant potency and pharmacokinetic data, we performed a literature search on PubMed, Google Scholar, BioRxiv, MedRxiv, and ChemRxiv. The following search terms were used for *in vitro* activity data – (COVID-19 OR SARS-CoV-2) AND (EC₅₀ OR IC₅₀ OR antiviral). For pharmacokinetic data (C_{max} OR pharmacokinetics) was used along with the drug name for drugs with reported anti-SARS-CoV-2 activity (up to April 13th 2020). Further clinical pharmacokinetic data was obtained from the Food and Drug Administration (FDA), the European Medicines Agency (EMA) and through publications available online.

Lung accumulation prediction

An indication of the degree to which candidate drugs are expected to accumulate in lung (a presumed site of primary efficacy and for prevention of SARS-CoV-2 infection) was provided by calculation of unbound lung to plasma tissue partition coefficient ($K_p U_{lung}$) according to the methodology of Rodgers and Rowland [20-22]. The formulae provided in these methods use the physicochemical properties of the drug (pKa, log P, classification as acid/base/neutral) and *in vitro* drug binding information (fraction unbound in plasma, blood to plasma ratio), in combination with tissue specific data (lipid content, volumes of intra/extracellular water etc.) to predict tissue $K_p U$ values. Predicted $K_p U_{lung}$ was converted to K_{p_lung} by multiplying by fraction unbound in plasma to allow estimation of lung exposure from *in vivo* measurements of plasma concentration. In the absence of observed tissue distribution data the Rodgers and Rowland method is an accepted means to provide initial estimates of tissue partitioning for PBPK modelling, but with known limits on potential accuracy (generally predicted $K_p U$ is within 2-3 fold of observed tissue $K_p U$ values).

Data analysis and interpretation

Since in the majority of papers only an EC₅₀ value was available, concentration-response data were digitized using the Web Plot Digitizer[®] software. Graphs were then re-plotted in SigmaPlot 14.0 (Systat Software, Inc.) and curves were fitted to confirm EC₅₀ values and determine EC₉₀ values. A C_{max}/EC₅₀ and C_{max}/EC₉₀ ratio was then calculated for each drug for which previous evidence of clinical use in humans and availability of human pharmacokinetic data were available. Lung $K_p U$ values were also used in combination with reported C_{max} values to derive an estimate of lung exposure at C_{max} for

each drug. For a subset of molecules, the absence of available physicochemical or plasma protein binding parameters prohibited derivation of a K_pU estimate. For the remaining drugs, a lung C_{max}/EC_{50} and lung C_{max}/EC_{90} was calculated. Published plasma concentration – time data for the most promising candidates were also digitized (were available) and replotted to visually represent human pharmacokinetics relative to the calculated EC_{50} and EC_{90} data.

Results

Identified papers and methods

We identified 14 key studies that detailed the antiviral activity of 72 compounds [23-37]. The majority of the *in vitro* SARS-CoV-2 infection experiments were performed in Vero E6 cells (ATCC 1586) maintained in either DMEM or MEM. Other studies utilised Vero-hSLAM cells, VeroE6 cells expressing TMPRSS2 and the CACO-2 cell line to cultivate the virus. The following SARS-CoV-2 strains were used across studies; WA-1 strain - BEI #NR-52281; Brazil/RJ-314/2020; C-Tan-nCoV Wuhan strain 01; Wuhan/WIV04/2019; USA-WA1/2020; nCoV-2019BetaCoV/Wuhan/WIV04/2019; BetaCoV/Hong Kong/VM20001061/2020; Australia/VIC01/2020; β CoV/KOR/KCDC03/2020 and BavPat1/2020. Cells across all studies were infected with the virus with a multiplicity of infection (MOI) of 0.002, 0.01, 0.0125, 0.02, 0.05 and 0.1. Drugs were added at concentrations varying between 0.01 μ M - 500 μ M. A summary of the differences in methodologies between studies reporting SARS-CoV-2 antiviral activity is presented in Table 1.

Identification of candidates achieving plasma concentrations expected to exert antiviral activity (C_{max} / EC₅₀ ratio)

Seventeen molecules had a reported C_{max} value greater than at least one of the reported EC₅₀ values against SARS-CoV-2 and these included nelfinavir, chloroquine, remdesivir, lopinavir (boosted with ritonavir), eltrombopag, hydroxychloroquine, atazanavir (boosted with ritonavir), indomethacin, favipiravir, sulfadoxine, niclosamide, mefloquine, tipranavir (boosted with ritonavir), ritonavir, merimepodib, anidulafungin and nitazoxanide. However, it should be noted that for amodiaquine, atazanavir, chloroquine, hydroxychloroquine, lopinavir, mefloquine, nelfinavir, remdesivir and toremifene, more than one EC₅₀ value had been reported across the available literature and these were not always in agreement (Figure 1A). Moreover, this variability in reported EC₅₀ values sometimes resulted in C_{max} / EC₅₀ ratios giving a different estimation of the likely value of the molecule. Meaning that for the same drug, the C_{max} / EC₅₀ ratio could be above or below 1 (Figure 1B). For amodiaquine and toremifene all reported EC₅₀ values were below their reported C_{max} and only for nelfinavir was the reported C_{max} expected to exceed both reported EC₅₀ values. For atazanavir, chloroquine, hydroxychloroquine, lopinavir, mefloquine and remdesivir, some EC₅₀ values were above the C_{max} whereas other were below. This observation dramatically highlights the sensitivity of the current analysis to the reported antiviral activity data, and this should be taken into account when interpreting the data presented hereafter.

Identification of candidates achieving plasma concentrations exceeding the SARS-CoV-2 EC₉₀ (C_{max} / EC₉₀ ratio)

For 57 of the reported antiviral activities, data covering a sufficient concentration range were available for digitisation and subsequent calculation of an EC₉₀ value. For the remainder it was not possible to calculate an EC₉₀. Drugs with an available EC₉₀ were ranked according to their C_{max}/EC₉₀ ratio (Figure 2). Drugs with a value above 1.0 achieved plasma concentrations above the concentrations reported to inhibit 90% of SARS-CoV-2 replication. Only eltrombopag, favipiravir, remdesivir, nelfinavir, niclosamide, nitazoxanide and tipranavir were estimated to exceed at least one of their reported EC₉₀ by 2-fold or more at C_{max} concentrations. Anidulafungin, lopinavir, chloroquine and ritonavir were also reported to exceed at least one of their reported EC₉₀ values at C_{max} but by less than 2-fold.

Detailed interrogation of the plasma pharmacokinetics in relation to reported anti-SARS-CoV-2 activity

For drugs with C_{max} concentrations above at least one of their reported EC₉₀ values that are not already in clinical trials for Covid-19, a detailed evaluation of concentrations across their approved dosing interval was undertaken. For this, published pharmacokinetics data were digitised and replotted relative to the calculated EC₅₀ and EC₉₀ data for SARS-CoV-2 (Figure 3). For tipranavir (boosted with ritonavir), nelfinavir, sulfadoxine and nitazoxanide plasma concentrations after administration of the approved dose remained above SARS-CoV-2 effective concentrations across the entire dosing interval. For antifungdaline, eltrombopag, lopinavir (boosted with ritonavir), mefloquine and chloroquine, C_{max} values were above EC₉₀ at 2, 6, 8, and 24 hours post dose respectively, but concentrations would be expected to dip below the EC₅₀ at 3, 8, 10, 72 and 120 hours post dose respectively when given at approved doses and schedules. An overview of these drugs is presented in Figure 2.

Simulated lung exposure relative to reported anti-SARS-CoV-2 activity

Lung K_{pU} was simulated for all molecules for which the necessary physicochemical properties and *in vitro* drug binding information were available. K_{pU_{lung}} was then used along with fraction unbound in plasma (F_u) and plasma C_{max} values to calculate a predicted C_{max}/EC₅₀ (Figure 3) and C_{max}/EC₉₀ in lung (data not shown). For 4 drugs, ebiselen, merimepodib, niclosamide and remdesivir, the fraction

unbound data were unavailable. For 6 other drugs, benztropine, indinavir, loperamide, nelfinavir, saquinavir and toremifene the blood to plasma ratios were unavailable. For a further 4 drugs, camostat, emetine, fluspirilene and umifenovir both fraction unbound and blood to plasma ratios were unavailable. Therefore, these drugs were excluded from the analysis. A total of 23 drugs with available data were predicted to give concentrations in lung above at least one of their reported EC_{50} against SARS-CoV-2 (Figure 4) and 8 of these were predicted to exceed their EC_{50} by more than 10-fold. The rank order of lung C_{max}/EC_{90} ratio was chloroquine > atazanavir (boosted with ritonavir) > tipranavir (boosted with ritonavir) > hydroxychloroquine > mefloquine > ivermectin > lopinavir (boosted with ritonavir) > azithromycin > ritonavir > gilteritinib > nitazoxanide > imantinib > oxprenolol (data excluded due to this analysis only being possible for 33 of the 56 drugs).

Discussion

The systematic development of mechanism-based inhibitors for key targets involved in viral replication or pathogenesis is likely to result in highly effective and safe medicines in the coming years. However, the repurposing of already approved medicines in antiviral treatment or chemoprevention strategies is undoubtedly the fastest way to bring forward therapeutic options against the urgent unmet need posed by SARS-CoV-2. A range of different drugs and drug classes have been demonstrated to display varying degrees of antiviral activity against SARS-CoV-2 *in vitro*, and many of these drugs are already licenced for use in humans for a range of indications. However, currently the data emerging from global screening efforts are not being routinely benchmarked and prioritised against achievable concentrations after administration of doses proven to have acceptable safety profiles in humans.

The current analysis indicates that only 12 drugs with reported antiviral activity are likely to achieve plasma exposures above that required for antiviral activity for at least some of their dosing interval. Notably, neither chloroquine, hydroxychloroquine nor lopinavir/ritonavir exhibited a sustained plasma concentration above their reported SARS-CoV-2 EC₉₀ across their reported dosing interval. Ultimately, the implications of this for therapy will depend upon whether systemic suppression is a prerequisite for a reduction in morbidity or mortality, but this does raise some concern for ongoing trials with these drugs (chloroquine: [NCT04323527](#); [NCT04333628](#) hydroxychloroquine: [NCT04316377](#); [NCT04333225](#); [NCT04307693](#) and lopinavir/ritonavir: [NCT04331834](#); [NCT04255017](#); [NCT04315948](#)). However, the predicted lung accumulation rather than plasma exposure may provide some therapy advantage and/or give more reassurance for ongoing chemoprevention trials.

At least 5 of the 13 candidates achieving C_{max} above one of their reported EC₅₀ and derived EC₉₀ are already in clinical evaluation for treatment of SARS-CoV-2. These include remdesivir ([NCT04292730](#); [NCT04292899](#); [NCT04257656](#); [NCT04252664](#); [NCT04315948](#)), favipiravir ([NCT04310228](#); [NCT04319900](#)), lopinavir/ritonavir and chloroquine. No robust antiviral activity data were found for galidesivir on which to conduct an analysis but it is also under clinical investigation ([NCT03800173](#)). A recent trial for favipiravir, demonstrated some success with an improvement over arbidol from 56% to 71% ($p = 0.02$) in patients without risk factors (but not critical cases or patients with hypertension and/or diabetes) [38]. The results of compassionate use of remdesivir in severely ill patients was also recently reported, and if confirmed in ongoing randomized, placebo-controlled trials will serve as a further validation of the other candidates presented here [39]. The authors are unaware of any ongoing COVID-19 trials for the other 7 candidate molecules with C_{max} above their reported EC₉₀, and none were reported on www.clinicaltrials.gov at the time of manuscript submission (14th April 2020).

Of particular interest nitazoxanide, tipranavir, sulfadoxine and nelfinavir may be expected to sustain their plasma pharmacokinetic exposure above their lowest reported EC_{50} and derived EC_{90} (where available) for the duration of their approved dose and dosing interval.

Nitazoxanide is an antiprotozoal drug that has previously been demonstrated to display broad antiviral activity against human and animal coronaviruses [40] as well as various strains of influenza [41, 42]. Importantly, nitazoxanide is rapidly metabolised to tizoxanide in humans and this active metabolite is being investigated against SARS-CoV-2 ([NCT04341493](#) and [NCT04343248](#)). Tizoxanide has been reported to exhibit similar activities to nitazoxanide for other viruses as well as other pathogens [43-45]. The mechanism of antiviral action is not fully understood for nitazoxanide, but it has been reported to affect viral genome synthesis, prevent viral entry and interfere with the N-glycosylation and maturation of the influenza hemagglutinin [46-49]. Notably, the SARS-CoV-2 spike protein is also highly N-glycosylated [50]. This drug has also been shown to elicit an innate immune response that potentiates the production of type 1 interferons [46, 51] and a phase 2b/3 clinical trial demonstrated a reduction in symptoms and viral shedding in patients with uncomplicated influenza [42]. The safety of nitazoxanide is well understood, but it has not been fully investigated during renal or hepatic impairment. The antiviral activity of nitazoxanide for SARS-CoV-2 requires further study but the existing data for this drug are encouraging. Niclosamide is another antiprotozoal drug that exhibits broad antiviral activity due to its ability to perturb the pH-dependent membrane fusion required for virus entry [52] but it was reported to have no impact upon the attachment and entry of SARS-CoV-2 [53]. For MERS-CoV niclosamide was observed to inhibit SKP2 activity impairing viral replication [54]. Niclosamide has been reported to be well tolerated and does not influence vital organ functions [55]. However, it has low aqueous solubility and poor oral bioavailability [56] and despite a higher reported SARS-CoV-2 potency [28] than nitazoxanide [27], the C_{max}/EC_{90} ratio was slightly lower. There is a paucity of published pharmacokinetic data for niclosamide and this prohibited a thorough investigation of exposures in relation to activity over its entire dosing interval. Both nitazoxanide and niclosamide have also been reported to be potent antagonists of TMEM16A, calcium activated chloride channels that modulate bronchodilation [57].

Tipranavir and nelfinavir are HIV protease inhibitors [58] and both drugs ranked highly in terms of their C_{max} / EC_{90} ratio. Moreover, a more in-depth analysis demonstrated that the concentrations across the dosing interval for both these drugs remained above the calculated EC_{90} values at approved doses and schedules. Unlike nelfinavir, tipranavir has to be co-administered with a low dose of ritonavir to boost its pharmacokinetics via CYP3A4 inhibition [59]. Since ritonavir itself has been reported to exert anti-SARS-CoV-2 activity, this could be advantageous, but would need to be balanced against the much higher risk of drug-drug interactions that could negatively impact patient

management. The implications of drug interactions have already been raised for this reason with lopinavir/ritonavir use for COVID-19 [60] and are likely to be exacerbated with the higher ritonavir dose needed for tipranavir. Moreover, tipranavir has a black box warning from the FDA for fatal and nonfatal intracranial haemorrhage as well as severe hepatotoxicity [61-63]. The major route of metabolic clearance for nelfinavir is via CYP2C19 and this pathway generates the M8 metabolite that retains activity against the HIV protease [64]. No data are available for inhibition of SARS-CoV-2 replication by the M8 metabolite but if active, this could provide an advantage for nelfinavir over tipranavir for COVID-19. Conversely, While the analysis of pharmacokinetics relative to potency of these molecules against SARS-CoV-2 is encouraging, it should be noted that the reported *in vitro* activity for HIV [58, 65] is far higher than that against SARS-CoV-2 and both drugs are highly protein bound [66, 67]. While older HIV protease inhibitors like tipranavir and nelfinavir are associated with long-term toxicities [58, 68-70] these may be less of a concern over shorter term exposure if they prove to be successful for COVID-19.

Sulfadoxine is another antimalarial drug that is usually administered in combination with pyrimethamine as a folic acid antagonist combination [71]. Sulfadoxine inhibits the activity of dihydropteroate synthase within the malaria parasite, but its mechanism of action for SARS-CoV-2 is unclear. It should also be noted that the authors can find no data describing antiviral activity of this drug against other viruses. Also, the concentrations used in the *in vitro* activity used in this analysis [26] were not high enough to reach or calculate an EC₉₀ value. Therefore, like other molecules described in this manuscript *in vitro* anti-SARS-CoV-2 activity should be repeated. Notwithstanding, sulfadoxine plasma concentrations far above the reported EC₅₀ are maintained in patients receiving a single 1500 mg dose (with 75 mg pyrimethamine) for over 40 days [72]. Compared to some other reported molecules sulfadoxine is not expected to have as high an accumulation in the lungs, but concentrations higher than its EC₅₀ are estimated from the analysis of its lung KpU. Therefore, if the reported antiviral activity is confirmed this drug may offer opportunities for therapy and/or chemoprophylaxis.

Considering that most of the impact of severe disease occurs in the lung and that this tissue may be a key site for transmission, the potential of candidate drugs to accumulate in lung tissue was considered. The analysis of predicted lung C_{max} / EC₅₀ ratio revealed more candidates expected to exceed the concentrations needed for antiviral activity in this tissue. Hydroxychloroquine, chloroquine, mefloquine, atazanavir (boosted with ritonavir), tipranavir (boosted with ritonavir), ivermectin and lopinavir were all predicted to achieve lung concentrations over 10-fold higher than their reported EC₅₀. All of these drugs were also predicted to exceed their EC₉₀ in lung by at least 3.4-fold (data not shown). The lung prediction was not possible for nelfinavir because insufficient data were available to

calculate $K_p U_{lung}$ but nitazoxanide and sulfadoxine were also predicted to exceed their reported EC_{50} by 3.1- and 1.5-fold in lung, respectively. Nitazoxanide was predicted to exceed its EC_{90} by 1.4-fold in lung but an EC_{90} was not calculable from the available data for sulfadoxine.

During inflammation or injury, changes to the vascular microenvironment, could have a profound effect on the ability of these drugs to accumulate in lung cells. Due to the recruitment of neutrophils and leaky endothelial cells [73], the lung inflammatory microenvironment is characterized by increased body temperature, excessive enzymic activity and most importantly, by a low interstitial pH [74]. In the case of chloroquine and hydroxychloroquine, these diprotic weak bases are exquisitely dependent on a pH gradient to drive lysosomal uptake as a mechanism of lung accumulation. It has been demonstrated that cellular chloroquine uptake is diminished one hundred-fold for every pH unit of external acidification [75]. This situation is likely to deteriorate further on mechanical ventilation, which also induces acidification of the lung tissue, independently of inflammation [76, 77]. Therefore, the benefits of lung accumulation for many of these drugs may be lost during treatment of severe SARS-CoV-2 infection. Conversely, mefloquine is monoprotic and more lipophilic than chloroquine, which may make it much less reliant on the pH gradient to drive cellular accumulation in lung. It is likely that the charged form of the drug is sufficiently lipophilic to allow movement across biological membranes along a concentration gradient [78]. Only two studies have described mefloquine uptake into cells, one study suggested that mefloquine uptake is not energy-dependent and the other suggested that mefloquine uptake is mediated by secondary active transport, rather than passive proton trapping [79, 80]. Mefloquine is known to cause severe psychiatric side effects in some patients and so use of this drug should be managed with care [81]. Therefore, mefloquine may offer opportunities for treatment during severe disease that are not available with other drugs currently being tested for COVID-19 therapy. If the high lung exposures are proven empirically for the drugs on this list, then some may also prove to be valuable for chemoprevention strategies.

Limitations of this analysis

This study represents the first holistic view of drugs with reported activity against SARS-CoV-2 in the context of their achievable pharmacokinetic exposure in humans. While the analysis does provide a basis to rationally selected candidates for further analysis, there are some important limitations. Firstly, C_{max} was the only pharmacokinetic parameter that was universally available for all of the candidate drugs, but C_{min} values are generally accepted as a better marker of efficacy since they represent the lowest plasma concentration over the dosing interval. However, C_{max} was only used to

assess whether plasma concentration would exceed those required at any point in the dosing interval, and this was followed by a more in-depth analysis of the most promising candidates.

Secondly, an EC₅₀ value only equates to a concentration required to suppress 50% of the virus, and data were unavailable to calculate EC₉₀ values for some of the drugs. EC₉₀ values are a preferred marker of activity because the slope of the concentration-response curve can vary substantially between different molecules and between different mechanisms of action. Although EC₉₀ were not calculable for all drugs the authors deemed it appropriate to deprioritise molecules not achieving EC₅₀ at C_{max} in this analysis. Thirdly, the reported antiviral activities were conducted under different conditions (Table 1) and in several cases varied between the same molecule assessed in different studies (Figure 1). No mitigation strategy was possible for this limitation and the data should be interpreted in the context that the quality of the available data may profoundly impact the conclusions. Furthermore *in vitro* activity should be confirmed for the promising candidates.

Fourthly, plasma protein binding can be an important factor in determining whether sufficient free drug concentration are available to exert antiviral activity [86] and insufficient data were available across the dataset to determine protein binding-adjusted EC₉₀ values. This is important because for highly protein bound drugs the antiviral activity in plasma may be lower than reported *in vitro* activity because protein concentrations used in culture media are lower than those in plasma. Fifthly, robust pharmacokinetic data were not available for all the molecules and subtle differences have been reported in the pharmacokinetics in different studies. Where possible, this analysis utilised the pharmacokinetics described at the highest doses approved for other indications and checked them to ensure that profound differences were not evident between different studies. However, in some cases higher doses and/or more frequent dosing has been investigated for some of the drugs mentioned so higher exposures may be available for some drugs with off-label dosing. Sixthly, the digitised pharmacokinetic plots presented in this manuscript represent the mean or median profiles depending on what was presented in the original manuscripts. Many of the drugs presented are known to exhibit high inter-individual variability that is not captured within the presented analysis and it is possible that even for promising candidates a significant proportion of patients may have sub-therapeutic concentrations despite population mean/median being higher than the C_{max}. Advanced pharmacokinetics modelling approaches will be needed to unpick this and are currently underway by the authors.

Seventhly, the presented predictions for lung accumulation may offer a basis for ranking molecules for expected accumulation in that organ, but ultimate effectiveness of a chemoprophylactic approach will likely depend upon penetration into other critical matrices in the upper airways, for which there

are currently no robustly validated methods of prediction. Also, while a generally accepted method for assessing KpU was employed, the predictions are not supported by any empirical investigation of the lung accumulation.

Finally, this analysis assumes that drugs need to be active within the systemic compartment in order to have efficacy against SARS-CoV-2. Since current evidence suggests that the virus is widely disseminated throughout the body this is a logical assumption. However, ultimate efficacy of any drug can only be demonstrated with robust clinical trial designs.

Summary

The current analysis reveals that many putative agents are never likely to achieve target concentrations necessary to adequately suppress SARS-CoV-2 under normal dosing conditions. It is critical that candidate medicines emerging from *in vitro* antiviral screening programmes are considered in the context of their expected exposure in humans where possible. Clinical trials are extremely time consuming and expensive, and it is critical that only the best options are progressed for robust analysis as potential mono- or combination therapy or prevention options. Finally, it would be highly beneficial for activity data for SARS-CoV-2 to be performed with standardised protocol and with activity reported as EC₉₀ values as a better marker of the concentrations required to suppress the virus to therapeutically relevant levels.

References

1. Gu, J., B. Han, and J. Wang, *COVID-19: Gastrointestinal manifestations and potential fecal-oral transmission*. Gastroenterology, 2020.
2. World Health Organisation, *COVID-19 Trials - International Clinical Trials Registry Platform (ICTRP)*. 2020.
3. Qin, C., et al., *Dysregulation of immune response in patients with COVID-19 in Wuhan, China*. Clin Infect Dis, 2020.
4. Li, W., et al., *Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus*. Nature, 2003. **426**(6965): p. 450-454.
5. Zhao, Y., et al., *Single-cell RNA expression profiling of ACE2, the receptor of SARS-CoV-2*. 2020: p. 2020.01.26.919985.
6. Wu, Y., et al., *Prolonged presence of SARS-CoV-2 viral RNA in faecal samples*. Lancet Gastroenterol Hepatol, 2020.
7. Diao, B., et al., *Human Kidney is a Target for Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection*. 2020: p. 2020.03.04.20031120.
8. Zhang, C., L. Shi, and F.S. Wang, *Liver injury in COVID-19: management and challenges*. Lancet Gastroenterol Hepatol, 2020.
9. Guo, Y.R., et al., *The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status*. Mil Med Res, 2020. **7**(1): p. 11.
10. Hoffmann, M., et al., *SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor*. Cell, 2020.
11. Zhang, H., et al., *The digestive system is a potential route of 2019-nCov infection: a bioinformatics analysis based on single-cell transcriptomes*. 2020: p. 2020.01.30.927806.
12. Wong, S.H., R.N. Lui, and J.J. Sung, *Covid-19 and the Digestive System*. J Gastroenterol Hepatol, 2020.
13. Zhang, W., et al., *Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes*. Emerg Microbes Infect, 2020. **9**(1): p. 386-389.
14. Sun, C.-b., et al., *Role of the Eye in Transmitting Human Coronavirus: What We Know and What We Do Not Know*. 2020.
15. Lu, C.W., X.F. Liu, and Z.F. Jia, *2019-nCoV transmission through the ocular surface must not be ignored*. Lancet, 2020. **395**(10224): p. e39.
16. Smith, C.A., et al., *Influenza virus inoculum volume is critical to elucidate age-dependent mortality in mice*. Aging Cell, 2019. **18**(2): p. e12893.
17. Miller, D.S., T. Kok, and P. Li, *The virus inoculum volume influences outcome of influenza A infection in mice*. Lab Anim, 2013. **47**(1): p. 74-7.
18. Chen, X., et al., *Detectable serum SARS-CoV-2 viral load (RNAemia) is closely associated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients*. 2020: p. 2020.02.29.20029520.
19. Liu, Y., et al., *Viral dynamics in mild and severe cases of COVID-19*. Lancet Infect Dis, 2020.
20. Rodgers, T., D. Leahy, and M. Rowland, *Physiologically based pharmacokinetic modelling 1: predicting the tissue distribution of moderate-to-strong bases*. J Pharm Sci, 2005. **94**(6): p. 1259-76.
21. Rodgers, T. and M. Rowland, *Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions*. J Pharm Sci, 2006. **95**(6): p. 1238-57.
22. Rodgers, T. and M. Rowland, *Mechanistic approaches to volume of distribution predictions: understanding the processes*. Pharm Res, 2007. **24**(5): p. 918-33.
23. Weston, S., et al., *FDA approved drugs with broad anti-coronaviral activity inhibit SARS-CoV-2 *in vitro**. 2020: p. 2020.03.25.008482.

24. Ge, Y., et al., *A data-driven drug repositioning framework discovered a potential therapeutic agent targeting COVID-19*. 2020: p. 2020.03.11.986836.
25. Bojkova, D., et al., *SARS-CoV-2 and SARS-CoV differ in their cell tropism and drug sensitivity profiles*. 2020: p. 2020.04.03.024257.
26. Touret, F., et al., *In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication*. 2020: p. 2020.04.03.023846.
27. Wang, M., et al., *Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro*. Cell Res, 2020. **30**(3): p. 269-271.
28. Jeon, S., et al., *Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs*. 2020: p. 2020.03.20.999730.
29. Xu, T., et al., *Indomethacin has a potent antiviral activity against SARS CoV-2 in vitro and canine coronavirus in vivo*. 2020: p. 2020.04.01.017624.
30. Fintelman-Rodrigues, N., et al., *Atazanavir inhibits SARS-CoV-2 replication and pro-inflammatory cytokine production*. 2020: p. 2020.04.04.020925.
31. Yamamoto, N., et al., *Nelfinavir inhibits replication of severe acute respiratory syndrome coronavirus 2 in vitro*. 2020: p. 2020.04.06.026476.
32. Bukreyeva, N., et al., *The IMPDH inhibitor merimepodib suppresses SARS-CoV-2 replication in vitro*. 2020: p. 2020.04.07.028589.
33. Jin, Z., et al., *Structure of Mpro from COVID-19 virus and discovery of its inhibitors*. Nature, 2020.
34. Yao, X., et al., *In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)*. Clin Infect Dis, 2020.
35. Choy, K.-T., et al., *Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro*. Antiviral Research, 2020. **178**: p. 104786.
36. Caly, L., et al., *The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro*. Antiviral Research, 2020: p. 104787.
37. Zhijian, X., et al., *Nelfinavir Is Active Against SARS-CoV-2 in Vero E6 Cells*. 2020.
38. Chen, C., et al., *Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial*. 2020: p. 2020.03.17.20037432.
39. Grein, J., et al., *Compassionate Use of Remdesivir for Patients with Severe Covid-19*. 2020.
40. Rossignol, J.F., *Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus*. J Infect Public Health, 2016. **9**(3): p. 227-30.
41. Tilmanis, D., et al., *The susceptibility of circulating human influenza viruses to tizoxanide, the active metabolite of nitazoxanide*. Antiviral Res, 2017. **147**: p. 142-148.
42. Haffizulla, J., et al., *Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trial*. Lancet Infect Dis, 2014. **14**(7): p. 609-18.
43. Gekonge, B., M.C. Bardin, and L.J. Montaner, *Short communication: Nitazoxanide inhibits HIV viral replication in monocyte-derived macrophages*. AIDS Res Hum Retroviruses, 2015. **31**(2): p. 237-41.
44. Tilmanis, D., et al., *The susceptibility of circulating human influenza viruses to tizoxanide, the active metabolite of nitazoxanide*. Antiviral Research, 2017. **147**: p. 142-148.
45. Trabattoni, D., et al., *Thiazolides Elicit Anti-Viral Innate Immunity and Reduce HIV Replication*. Scientific Reports, 2016. **6**(1): p. 27148.
46. Rossignol, J.F., *Nitazoxanide: a first-in-class broad-spectrum antiviral agent*. Antiviral Res, 2014. **110**: p. 94-103.
47. Rossignol, J.F., et al., *Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level*. J Biol Chem, 2009. **284**(43): p. 29798-808.
48. Hickson, S.E., et al., *Inhibition of vaccinia virus replication by nitazoxanide*. Virology, 2018. **518**: p. 398-405.

49. Wang, Y.M., et al., *Antiviral activities of niclosamide and nitazoxanide against chikungunya virus entry and transmission*. Antiviral Res, 2016. **135**: p. 81-90.
50. Zhang, Y., et al., *Site-specific N-glycosylation Characterization of Recombinant SARS-CoV-2 Spike Proteins using High-Resolution Mass Spectrometry*. 2020: p. 2020.03.28.013276.
51. Clerici, M., et al., *The anti-infective Nitazoxanide shows strong immunomodulating effects (155.21)*. 2011. **186**(1 Supplement): p. 155.21-155.21.
52. Jurgeit, A., et al., *Niclosamide is a proton carrier and targets acidic endosomes with broad antiviral effects*. PLoS Pathog, 2012. **8**(10): p. e1002976.
53. Zhang, X.W. and Y.L. Yap, *Old drugs as lead compounds for a new disease? Binding analysis of SARS coronavirus main proteinase with HIV, psychotic and parasite drugs*. Bioorg Med Chem, 2004. **12**(10): p. 2517-21.
54. Gassen, N.C., et al., *SKP2 attenuates autophagy through Beclin1-ubiquitination and its inhibition reduces MERS-Coronavirus infection*. Nat Commun, 2019. **10**(1): p. 5770.
55. Li, R., et al., *Inhibition of STAT3 by niclosamide synergizes with erlotinib against head and neck cancer*. PLoS One, 2013. **8**(9): p. e74670.
56. Lin, C.K., et al., *Preclinical evaluation of a nanoformulated antihelminthic, niclosamide, in ovarian cancer*. Oncotarget, 2016. **7**(8): p. 8993-9006.
57. Miner, K., et al., *Drug Repurposing: The Anthelmintics Niclosamide and Nitazoxanide Are Potent TMEM16A Antagonists That Fully Bronchodilate Airways*. Front Pharmacol, 2019. **10**: p. 51.
58. Lv, Z., Y. Chu, and Y. Wang, *HIV protease inhibitors: a review of molecular selectivity and toxicity*. HIV AIDS (Auckl), 2015. **7**: p. 95-104.
59. Streeck, H. and J.K. Rockstroh, *Review of tipranavir in the treatment of drug-resistant HIV*. Ther Clin Risk Manag, 2007. **3**(4): p. 641-51.
60. Sanders, J.M., et al., *Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review*. JAMA, 2020.
61. Justice, A.C., et al., *Drug Toxicity, HIV Progression, or Comorbidity of Aging: Does Tipranavir Use Increase the Risk of Intracranial Hemorrhage?* Clinical Infectious Diseases, 2008. **47**(9): p. 1226-1230.
62. Flexner, C., G. Bate, and P. Kirkpatrick, *Tipranavir*. Nature Reviews Drug Discovery, 2005. **4**(12): p. 955-956.
63. Chan-Tack, K.M., K.A. Struble, and D.B. Birnkrant, *Intracranial hemorrhage and liver-associated deaths associated with tipranavir/ritonavir: review of cases from the FDA's Adverse Event Reporting System*. AIDS Patient Care STDS, 2008. **22**(11): p. 843-50.
64. Hirani, V.N., J.L. Raucy, and J.M. Lasker, *Conversion of the HIV protease inhibitor nelfinavir to a bioactive metabolite by human liver CYP2C19*. Drug Metab Dispos, 2004. **32**(12): p. 1462-7.
65. Zhang, K.E., et al., *Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma, and antiviral activities*. Antimicrob Agents Chemother, 2001. **45**(4): p. 1086-93.
66. Motoya, T., et al., *Characterization of nelfinavir binding to plasma proteins and the lack of drug displacement interactions*. HIV Med, 2006. **7**(2): p. 122-8.
67. King, J.R. and E.P. Acosta, *Tipranavir*. Clinical Pharmacokinetics, 2006. **45**(7): p. 665-682.
68. Markowitz, M., et al., *Long-term efficacy and safety of tipranavir boosted with ritonavir in HIV-1-infected patients failing multiple protease inhibitor regimens: 80-week data from a phase 2 study*. J Acquir Immune Defic Syndr, 2007. **45**(4): p. 401-10.
69. Justice, A.C., et al., *Drug toxicity, HIV progression, or comorbidity of aging: does tipranavir use increase the risk of intracranial hemorrhage?* Clin Infect Dis, 2008. **47**(9): p. 1226-30.
70. Unis, G., et al., *Mitochondrial Mechanisms of Nelfinavir Toxicity in Human Brain Microvascular Endothelial cells*. 2016. **30**(1_supplement): p. 953.4-953.4.

71. Lovegrove, F.E. and K.C. Kain, *Chapter 6 - Malaria Prevention*, in *The Travel and Tropical Medicine Manual (Fourth Edition)*, E.C. Jong and C. Sanford, Editors. 2008, W.B. Saunders: Edinburgh. p. 76-99.
72. de Kock, M., et al., *Pharmacokinetics of Sulfadoxine and Pyrimethamine for Intermittent Preventive Treatment of Malaria During Pregnancy and After Delivery*. CPT Pharmacometrics Syst Pharmacol, 2017. **6**(7): p. 430-438.
73. Pober, J.S. and W.C. Sessa, *Evolving functions of endothelial cells in inflammation*. Nat Rev Immunol, 2007. **7**(10): p. 803-15.
74. Zhang, R., et al., *Tumor-associated inflammatory microenvironment in non-small cell lung cancer: correlation with FGFR1 and TLR4 expression via PI3K/Akt pathway*. J Cancer, 2019. **10**(4): p. 1004-1012.
75. Geary, T.G., et al., *Kinetic modelling of the response of Plasmodium falciparum to chloroquine and its experimental testing in vitro. Implications for mechanism of action of and resistance to the drug*. Biochem Pharmacol, 1990. **40**(4): p. 685-91.
76. Pugin, J., et al., *Cyclic stretch of human lung cells induces an acidification and promotes bacterial growth*. Am J Respir Cell Mol Biol, 2008. **38**(3): p. 362-70.
77. Drachman, N., et al., *In vivo pH mapping of injured lungs using hyperpolarized [1-(13)C]pyruvate*. Magn Reson Med, 2017. **78**(3): p. 1121-1130.
78. Ginsburg, H., E. Nissani, and M. Krugliak, *Alkalinization of the food vacuole of malaria parasites by quinoline drugs and alkylamines is not correlated with their antimalarial activity*. Biochem Pharmacol, 1989. **38**(16): p. 2645-54.
79. Vanderkooi, G., P. Prapunwattana, and Y. Yuthavong, *Evidence for electrogenic accumulation of mefloquine by malarial parasites*. Biochem Pharmacol, 1988. **37**(19): p. 3623-31.
80. Fitch, C.D., R. Chevli, and Y. Gonzalez, *Chloroquine-resistant Plasmodium falciparum: effect of substrate on chloroquine and amodiaquin accumulation*. Antimicrob Agents Chemother, 1974. **6**(6): p. 757-62.
81. Ritchie, E.C., J. Block, and R.L. Nevin, *Psychiatric side effects of mefloquine: applications to forensic psychiatry*. J Am Acad Psychiatry Law, 2013. **41**(2): p. 224-35.
82. Hamaguchi, M., et al., *Successful treatment of non-HIV progressive multifocal leukoencephalopathy: case report and literature review*. J Neurol, 2020. **267**(3): p. 731-738.
83. Pham, Y.T., et al., *Cerebral uptake of mefloquine enantiomers in fatal cerebral malaria*. International journal of clinical pharmacology and therapeutics, 1999. **37**(1): p. 58-61.
84. Baig, A.M., et al., *Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanisms*. ACS Chem Neurosci, 2020. **11**(7): p. 995-998.
85. Wu, Y., et al., *Nervous system involvement after infection with COVID-19 and other coronaviruses*. Brain, Behavior, and Immunity, 2020.
86. Gonzalez, D., S. Schmidt, and H. Derendorf, *Importance of relating efficacy measures to unbound drug concentrations for anti-infective agents*. Clin Microbiol Rev, 2013. **26**(2): p. 274-88.
87. Fox, L.M. and L.D. Saravolatz, *Nitazoxanide: A New Thiazolide Antiparasitic Agent*. Clinical Infectious Diseases, 2005. **40**(8): p. 1173-1180.
88. la Porte, C.J., et al., *Lack of effect of efavirenz on the pharmacokinetics of tipranavir-ritonavir in healthy volunteers*. Antimicrob Agents Chemother, 2009. **53**(11): p. 4840-4.
89. Kruse, G., et al., *The steady-state pharmacokinetics of nelfinavir in combination with tenofovir in HIV-infected patients*. Antivir Ther, 2005. **10**(2): p. 349-55.
90. Rainsford, K.D., et al., *Effects of misoprostol on the pharmacokinetics of indomethacin in human volunteers*. Clin Pharmacol Ther, 1992. **51**(4): p. 415-21.
91. Burger, D.M., et al., *Effect of Rifampin on Steady-State Pharmacokinetics of Atazanavir with Ritonavir in Healthy Volunteers*. 2006. **50**(10): p. 3336-3342.

92. Tett, S.E., et al., *Concentration-effect relationship of hydroxychloroquine in patients with rheumatoid arthritis--a prospective, dose ranging study*. J Rheumatol, 2000. **27**(7): p. 1656-60.
93. Shida, Y., et al., *Pharmacokinetics and Pharmacodynamics of Eltrombopag in Healthy Japanese Males*. Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics, 2011. **42**(1): p. 11-20.
94. FDA. Abbott L. *Clinical Pharmacology and Biopharmaceutics review of Kaletra oral solution (NDA#021251)*. 2020 [cited 2020 13/04]; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-226_Kaletra_biopharmr_P1.pdf.
95. Na-Bangchang, K., et al., *The pharmacokinetics of chloroquine in healthy Thai subjects and patients with Plasmodium vivax malaria*. Br J Clin Pharmacol, 1994. **38**(3): p. 278-81.
96. Krudsood, S., et al., *New Fixed-Dose Artesunate-Mefloquine Formulation against Multidrug-Resistant Plasmodium falciparum in Adults: a Comparative Phase IIb Safety and Pharmacokinetic Study with Standard-Dose Nonfixed Artesunate plus Mefloquine*. 2010. **54**(9): p. 3730-3737.
97. Liu, P., et al., *Pharmacokinetics of anidulafungin in critically ill patients with candidemia/invasive candidiasis*. Antimicrob Agents Chemother, 2013. **57**(4): p. 1672-6.
98. Fintelman-Rodrigues, N., et al., *Atazanavir inhibits SARS-CoV-2 replication and pro-inflammatory cytokine production*. 2020: p. 2020.04.04.020925.
99. Raja, A., J. Lebbos, and P. Kirkpatrick, *Atazanavir sulphate*. Nature Reviews Drug Discovery, 2003. **2**(11): p. 857-858.
100. Harrison, T.S. and L.J. Scott, *Atazanavir*. Drugs, 2005. **65**(16): p. 2309-2336.
101. Murdoch, D. and G.L. Plosker, *Anidulafungin*. Drugs, 2004. **64**(19): p. 2249-2258.
102. Goel, P. and V. Gerriets, *Chloroquine*, in *StatPearls*. 2020: Treasure Island (FL).
103. Garnock-Jones, K.P., *Eltrombopag*. Drugs, 2011. **71**(10): p. 1333-1353.
104. PMDA. *Report on the Deliberation Results 2014* Available from: <https://www.pmda.go.jp/files/000210319.pdf>.
105. Ben-Zvi, I., et al., *Hydroxychloroquine: from malaria to autoimmunity*. Clin Rev Allergy Immunol, 2012. **42**(2): p. 145-53.
106. Yeh, K.C., *Pharmacokinetic overview of indomethacin and sustained-release indomethacin*. Am J Med, 1985. **79**(4C): p. 3-12.
107. Corbett, A.H., M.L. Lim, and A.D. Kashuba, *Kaletra (lopinavir/ritonavir)*. Ann Pharmacother, 2002. **36**(7-8): p. 1193-203.
108. Price, R.N., et al., *Artesunate/mefloquine treatment of multi-drug resistant falciparum malaria*. Trans R Soc Trop Med Hyg, 1997. **91**(5): p. 574-7.
109. McHutchison, J.G., et al., *A randomized, double-blind, placebo-controlled dose-escalation trial of merimepodib (VX-497) and interferon-alpha in previously untreated patients with chronic hepatitis C*. Antivir Ther, 2005. **10**(5): p. 635-43.
110. James, J.S., *Nelfinavir (Viracept) approved: fourth protease inhibitor available*. AIDS Treat News, 1997(No 267): p. 1-2.
111. Chen, W., et al., *Niclosamide: Beyond an antihelminthic drug*. Cellular Signalling, 2018. **41**: p. 89-96.
112. Anderson, V.R. and M.P. Curran, *Nitazoxanide*. Drugs, 2007. **67**(13): p. 1947-1967.
113. Porche, D.J., *Ritonavir (Norvir)*. J Assoc Nurses AIDS Care, 1997. **8**(6): p. 81-3.
114. Miller, K.D., et al., *Severe cutaneous reactions among American travelers using pyrimethamine-sulfadoxine (Fansidar) for malaria prophylaxis*. Am J Trop Med Hyg, 1986. **35**(3): p. 451-8.
115. Orman, J.S. and C.M. Perry, *Tipranavir: a review of its use in the management of HIV infection*. Drugs, 2008. **68**(10): p. 1435-63.

Figure legends

Figure 1. Assessment of the variation in reported EC_{50} values for SARS-CoV-2 across the drugs for which more than one value was available in the literature (A). The consequences of this variability in reported EC_{50} in terms of the C_{max} / EC_{50} ratio is also provided (B). Amodiaquine and toremifene were estimated to exhibit sub-therapeutic pharmacokinetics irrespective of which EC_{50} value was used. Similarly, nelfinavir was estimated to have C_{max} value higher than its EC_{50} irrespective of which EC_{50} was used in the analysis. For the other drugs, interpretation was highly dependent upon which reported EC_{50} was utilised and this underscores the caution that should be taken in interpreting the available data.

Figure 2. A bar chart displaying C_{max} / EC_{90} ratio for compounds studied for *in vitro* antiviral activity against SARS-CoV-2 for which data were available to recalculate an EC_{90} . Drugs with a ratio below 1 were deemed not to provide plasma concentrations at their approved doses to exert sufficient systemic antiviral activity. Those drugs with a ratio above 1 (shown in orange) were deemed to have potential to provide plasma concentrations sufficient to exert at least some antiviral activity for at least some of their dosing interval at their approved dose. Drugs shown in green were predicted to exceed plasma concentrations over their EC_{90} by more than a two-fold.

Figure 3. Digitised pharmacokinetic interrogation of all drugs calculated to have a C_{max} / EC_{50} ratio above 1. The lowest reported SARS-CoV-2 EC_{50} (dashed orange lines) and associated recalculated EC_{90} (dashed green lines) are also highlighted. References for the utilised data are nitazoxanide 500mg BID and 1000mg BID [87], tipranavir 500mg BID with 200mg ritonavir [88], sulfadoxine 1500mg with 75mg pyrimethamine [72], nelfinavir 1250mg BID [89], indomethacin 50mg TID [90], atazanavir 300mg QD with 100mg ritonavir [91], hydroxychloroquine 2000 mg hydroxychloroquine sulfate / 1550 mg base administered over 3 days [92], Eltrombopag 75mg single dose [93], lopinavir 400 mg with 100 mg ritonavir [94], chloroquine 1500mg administered over 3 days [95], mefloquine 1200mg over 3 days [96], anidulafungin 100 mg QD [97]. Robust pharmacokinetic data were unavailable for niclosamide 500mg, ritonavir 600mg and merimepodib 300mg in order to conduct this digitised interrogation of these molecules.

Figure 4. A bar chart displaying the simulated lung C_{max} / EC_{50} . Drugs with a ratio below 1 were deemed not to provide lung concentrations at their approved doses to exert sufficient pulmonary antiviral activity for treatment or prevention strategies. Those drugs with a ratio above 1 (shown in orange) were estimated to provide lung concentrations sufficient to exert at least some antiviral activity at their approved dose. Drugs shown in green were predicted to exceed lung concentrations over their EC_{50} by more than a ten-fold.

Figures

Figure 1

Figure 2

Figure 3

Figure 4

Tables

Table 1. Drugs investigated for SARS-CoV-2 antiviral activity and experimental overview

Drug name	Multiplicity of Infection (MOI)	Cell Type	Virus Strain	Concentration Range Tested	Viral Quantification	Approved clinical dose	Indication	Population in which PK was assessed	Ref	Link to regulatory description
Abemaciclib	0.0125	Vero E6 cells (ATCC CCL-81)	βCoV/KOR/KCD C03/2020)	0.05– 50 uM	Immunofluorescence	200 mg BID	Cancer	Patients with BC, NSCLC, other solid tumours	[28]	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208716s000lbl.pdf
Alprostadil	0.002	VeroE6 (ATCC CRL-1586)	BavPat1	0.6μM to 40μM	RT-PCR	360 ug QD (up to 500 ug for single topical use)	Induce vasodilation/Erectile dysfunction	Healthy male volunteers - IV infusion	[26]	https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020649s023lbl.pdf
Amodiaquine 1	0.0125	Vero E6 cells (ATCC CCL-81)	βCoV/KOR/KCD C03/2020)	0.05– 50 uM	Immunofluorescence	540 mg QD	Malaria	Healthy male Vietnamese volunteers	[28]	https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=006441 https://www.ema.europa.eu/en/documents/medicinal-products/pyramax-product-information_en.pdf
Amodiaquine 2	0.01	Vero E6 cells	WA-1 strain - BEI #NR-52281	0.4- 50 uM	plaque assay / TCID50/ qRT-PCR	10 mg/kg (single dose)	Malaria	Healthy Volunteers	[23]	https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=006441
Amodiaquine 3	0.01	Vero E6 cells	WA-1 strain - BEI #NR-52282	0.4- 50 uM	plaque assay / TCID50/ qRT-PCR	450 mg QD	Malaria	Healthy Volunteers	[23]	https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=006441
Amprenavir	0.01	VeroE6/TMP RSS2	No info	0.01-1000 uM	RT-PCR	600mg twice BID	HIV	HIV-1 infected patients	[31]	https://www.ema.europa.eu/en/documents/product-information/telzir-epar-product-information_en.pdf https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208716s000lbl.pdf

										essdata.fda.gov/drugsatfda_docs/label/2005/021007s017lbl.pdf
Anidulafungin	0.0125	Vero E6 cells (ATCC CCL-81)	βCoV/KOR/KCD C03/2020)	0.05– 50 uM	Immunofluorescence	Loading of 200 mg QD and subsequent 100 mg QD	Invasive candidiasis/candidaemia	Healthy volunteers	[28]	https://www.eur.ema.europa.eu/en/documents/variation-report/ecalta-h-c-788-p46-046-epar-assessment-report_en.pdf
Atazanavir 1	0.01	Vero E6	Brazil/RJ-314/2020	10- 1000 μM	RT-PCR	300/100 mg OD (with ritonavir)	HIV-1 infection	Healthy male volunteers	[98]	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021567_reyataz_toc.cfm
Atazanavir 2	0.01	VeroE6/TMP RSS2	No info	0.01-1000 uM	RT-PCR	300/100 mg OD (with ritonavir)	HIV-1 infection	Healthy male volunteers	[31]	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021567_reyataz_toc.cfm
Azithromycin	0.002	VeroE6 (ATCC CRL-1586)	BavPat1	0.6μM to 40μM	RT-PCR	500 mg QD	Used to treat a range of bacterial infections	Healthy male volunteers	[26]	https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050710s039_050711s036_050784s023lbl.pdf
Baricitinib	0.01	Vero E6 cells	WA-1 strain - BEI #NR-52283	0.4- 50 uM	plaque assay / TCID50/ qRT-PCR	20 mg QD	Rheumatoid arthritis	Healthy Volunteers	[23]	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/207924Orig1s000ClinPharmR.pdf
Bazedoxifene	0.0125	Vero E6 cells (ATCC CCL-81)	βCoV/KOR/KCD C03/2020)	0.05– 50 uM	Immunofluorescence	40 mg QD	Treatment of osteoporosis in postmenopausal women	Healthy postmenopausal women	[23]	https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022247Orig1s001lbl.pdf
Benzotropine	0.01	Vero E6 cells	WA-1 strain - BEI #NR-52284	0.4- 50 uM	plaque assay / TCID50/ qRT-PCR	1.5 mg QD	Parkinson's disease	Healthy Volunteers	[23]	https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=040715
Camostat	0.0125	Vero E6 cells (ATCC CCL-81)	βCoV/KOR/KCD C03/2020)	0.05– 50 uM	Immunofluorescence	200 mg TID	Pancreatitis	Can only find single dose PK	[23]	https://www.accessdata.fda.gov/scripts/opdlisting/oodp/detailedindex.cfm?cfgridkey=338211

Chloroquine 1	0.05	Vero E6 cells (ATCC-1586)	Wuhan/WIV04/2022	1-1000	qRT-PCR/ NP expression, immunofluorescence	1500 mg over 3 days	Malaria	Healthy Thai subjects	[27]	https://www.fda.gov/media/136535/download
Chloroquine 2	0.0125	Vero E6 cells (ATCC CCL-81)	βCoV/KOR/KCD C03/2020)	0.05– 50 uM	Immunofluorescence	1500 mg over 3 days	Malaria	Healthy Thai subjects	[28]	https://www.fda.gov/media/136535/download
Chloroquine 3	0.05	Vero E6 cells (ATCC CCL-81)	βCoV/KOR/KCD C03/2020)	0.05– 50 uM	CPE	1500 mg over 3 days	Malaria	Healthy Thai subjects	[28]	https://www.fda.gov/media/136535/download
Chloroquine 4	0.01	Vero cells	C-Tan-nCoV Wuhan strain 01	0.032 - 100 uM	RT-PCR	1500 mg over 3 days	Malaria	Healthy Thai subjects	[34]	https://www.fda.gov/media/136535/download
Chloroquine 5	0.01	Vero E6 cells	WA-1 strain - BEI #NR-52285	0.4- 50 uM	plaque assay / TCID50/ qRT-PCR	1500 mg over 3 days	Malaria	Healthy Thai subjects	[23]	https://www.fda.gov/media/136535/download
Chlorpromazine	0.01	Vero E6 cells	WA-1 strain - BEI #NR-52286	0.4- 50 uM	plaque assay / TCID50/ qRT-PCR	100 mg (single dose)	Antipsychotic	Healthy male volunteers	[23]	https://www.accessdata.fda.gov/drugsatfda_docs/psg/Chlorpromazine%20Hydrochloride%20Oral%20Tablet%20AND%2084114%20RV%2009-2018.pdf
Ciclesonide	0.0125	Vero E6 cells (ATCC CCL-81)	βCoV/KOR/KCD C03/2020)	0.05– 50 uM	Immunofluorescence	360 µg QD (inhaled only)	Treatment of asthma	37 pediatric patients with Asthma	[28]	https://www.fda.gov/media/71478/download
Clomipramine	0.01	Vero E6 cells	WA-1 strain - BEI #NR-52287	0.4- 50 uM	plaque assay / TCID50/ qRT-PCR	150 mg QD	Treatment of Obsessive-Compulsive Disorder	Healthy volunteers	[23]	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019906s037lbl.pdf
Cyclosporine	0.0125	Vero E6 cells (ATCC CCL-81)	βCoV/KOR/KCD C03/2020)	0.05– 50 uM	Immunofluorescence	100 mg QD	Immunosuppressant	Healthy volunteers	[28]	https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050573s039,050574s047,050625s053bl.pdf
Darunavir	0.01	VeroE6/TMP RSS2	No info	0.01-1000 uM	RT-PCR	600/100 mg BID (with ritonavir)	HIV	Adult patients Coinfected with Hepatitis C and HIV	[31]	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021976s021lbl.pdf

Digitoxin	0.0125	Vero E6 cells (ATCC CCL-81)	βCoV/KOR/KCD C03/2020)	0.05– 50 uM	Immunofluorescence	0.56 mg (single dose)	Cardiovascular/Cancer	Healthy volunteers	[28]	https://www.accessdata.fda.gov/scripts/opdlisting/ocpd/detailedindex.cfm?cfgridkey=149701
Digoxin	0.0125	Vero E6 cells (ATCC CCL-81)	βCoV/KOR/KCD C03/2020)	0.05– 50 uM	Immunofluorescence	2 mg loading QD then 0.5 mg QD	Cardiovascular	Healthy volunteers	[28]	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020405s013lbl.pdf
Dolutegravir	0.002	VeroE6 (ATCC CRL-1586)	BavPat1	0.6μM to 40μM	RT-PCR	50 mg BID	HIV	Healthy volunteers	[26]	https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204790lbl.pdf
Ebselen	0.05	Vero Cells (ATCC)	No info	0.4-100um	Plaque-reduction assay	1600 mg (single dose)	Prevention and treatment of noise induced hearing loss	Healthy volunteers	[33]	In development
Eltrombopag	0.0125	Vero E6 cells (ATCC CCL-81)	βCoV/KOR/KCD C03/2020)	0.05– 50 uM	Immunofluorescence	75 mg QD	Idiopathic thrombocytopenic purpura (ITP)	Healthy adult Japanese males	[28]	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207027s003lbl.pdf
Emetine	0.02	VeroE6 (ATCC CRL-1586)	BetaCoV/Hong Kong/VM20001 061/2020,	No info	TCID50 assay/ qRT-PCR	30 ml syrup of Ipecac (single dose)	Not approved	Healthy volunteers, aged 18 - 45	[35]	-
Favipiravir	0.05	Vero E6 cells (ATCC-1586)	Wuhan/WIV04/2019	1-1000	qRT-PCR/ NP expression, immunofluorescence	600 mg BID	Ebola	Healthy volunteers	[27]	Not FDA approved
Fluphenazine	0.01	Vero E6 cells	WA-1 strain - BEI #NR-52288	0.4- 50 uM	plaque assay / TCID50/ qRT-PCR	25 mg IM at SS	Antipsychotic	Patients receiving chronic neuroleptic maintenance	[23]	https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&AppNo=089586
Fluspirilene	0.01	Vero E6 cells	WA-1 strain - BEI #NR-52289	0.4- 50 uM	plaque assay / TCID50/ qRT-PCR	2 mg IM dosed weekly	Antipsychotic	Healthy volunteers	[23]	Discontinued
Gilteritinib	0.0125	Vero E6 cells (ATCC CCL-81)	βCoV/KOR/KCD C03/2020)	0.05– 50 uM	Immunofluorescence	120 mg QD	Relapsed or refractory acute myeloid leukemia	Patients with relapsed or refractory AML	[28]	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211349s000lbl.pdf

Homoharringtonine	0.02	VeroE6 (ATCC CRL-1586)	BetaCoV/Hong Kong/VM20001 061/2020,	No info	TCID50 assay/ qRT-PCR	1.25 mg/m2 BID	chronic myeloid leukemia	Adult patients with a diagnosis of relapsed or refractory CML	[35]	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203585Orig1s000SumR.pdf
Hydroxychloroquine 1	0.01	Vero cells	C-Tan-nCoV Wuhan strain 01	0.032 - 100 uM	RT-PCR	400mg daily	Rheumatoid arthritis	Patients with rheumatoid arthritis	[34]	https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=040274
Hydroxychloroquine 2	0.01	Vero E6 cells	WA-1 strain - BEI #NR-52290	0.4- 50 uM	plaque assay / TCID50/ qRT-PCR	400mg daily	Rheumatoid arthritis	Patients with rheumatoid arthritis	[23]	https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=040274
Hydroxyprogesterone	0.0125	Vero E6 cells (ATCC CCL-81)	βCoV/KOR/KCD C03/2020)	0.05– 50 uM	Immunofluorescence	250 mg IM (single dose)	Reduces the rate of recurrent preterm birth	Pregnant women	[28]	https://www.fda.gov/media/132003/download
Imatinib	0.01	Vero E6 cells	WA-1 strain - BEI #NR-52291	0.4- 50 uM	plaque assay / TCID50/ qRT-PCR	400mg BID	Cancer	Healthy volunteers	[23]	https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021588s024lbl.pdf
Indinavir	0.01	VeroE6/TMP RSS2	No info	0.01-1000 uM	RT-PCR	800mg TID	HIV-1 infection	HIV-1 infected patients	[31]	https://www.european.eu/en/documents/scientific-discussion/crixivan-epar-scientific-discussion_en.pdf
Indomethacin	5 ng pseudotyped virus	Vero E6	cDNA used to create pseudotyped virus, GenBank: MN908947.3	0.1-500uM	Luciferase labelled	50 mg TID	acute painful shoulder (bursitis and/or tendinitis)	Healthy male volunteers 20-32 yrs, mostly Caucasian	[29]	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/016059s100lbl.pdf
Ivacaftor	0.0125	Vero E6 cells (ATCC CCL-81)	βCoV/KOR/KCD C03/2020)	0.05– 50 uM	Immunofluorescence	150 mg BID	Cystic fibrosis	Healthy volunteers	[28]	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/203188s019lbl.pdf
Ivermectin	0.1	Vero/hSLAM	Australia/VIC01 /2020 isolate)	0.1-10 uM	RT-PCR	200microg/Kg (single dose)	Strongyloidiasis	Healthy volunteers (mainly male)	[36]	https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050742s022lbl.pdf

Loperamide	0.0125	Vero E6 cells (ATCC CCL-81)	βCoV/KOR/KCD C03/2020)	0.05– 50 uM	Immunofluorescence	8 mg (single dose)	Anti-diarrhoeal medication	Healthy Malaysian male volunteers aged 21-55	[28]	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/017694s052lbl.pdf
Lopinavir 1	0.01	VeroE6/TMP RSS2	No info	0.01-1000 uM	RT-PCR	400/100 mg Kaletra BID	HIV	Healthy male volunteers	[31]	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-226_Kaletra.cfm
Lopinavir 2	0.0125	Vero E6 cells (ATCC CCL-81)	βCoV/KOR/KCD C03/2020)	0.05– 50 uM	Immunofluorescence	400/100 mg Kaletra BID	HIV	Healthy male volunteers	[28]	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-226_Kaletra.cfm
Lopinavir 3	0.05	Vero E6 cells (ATCC CCL-81)	βCoV/KOR/KCD C03/2020)	0.05–50 μM	CPE	400/100 mg Kaletra BID	HIV	Healthy male volunteers	[28]	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-226_Kaletra.cfm
Mefloquine 1	0.0125	Vero E6 cells (ATCC CCL-81)	βCoV/KOR/KCD C03/2020)	0.05– 50 uM	Immunofluorescence	250 mg	Malaria	Adult Thai males with, 17-48 years	[28]	https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/019591s024s025lbl.pdf
Mefloquine 2	0.01	Vero E6 cells	WA-1 strain - BEI #NR-52281	0.4- 50 uM	plaque assay / TCID50/ qRT-PCR	250 mg	Malaria	Adult Thai males with, 17-48 years	[23]	https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/019591s024s025lbl.pdf
Merimepodib	0.05	Vero	SARS-CoV-2 USA-WA1/2020	1493 - 4525 ng/ml		300 mg TID	HCV / not currently approved	HCV+ patients, 18-70 years	[32]	-
Nelfinavir 1	0.01	VeroE6/TMP RSS2 cells	No info	0.01-1000 uM	RT-PCR	1250 mg BID	HIV	HIV+ patients, 62% male, mean age 49	[31]	https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021503s006lbl.pdf
Nelfinavir 2	0.01	VeroE6/TMP RSS2	No info	0.01-1000 uM	RT-PCR	1250 mg BID	HIV	HIV+ patients, 62% male, mean age 49	[29]	https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021503s006lbl.pdf
Niclosamide	0.0125	Vero E6 cells (ATCC CCL-81)	βCoV/KOR/KCD C03/2020)	0.05– 50 uM	Immunofluorescence	2000 mg OD	Anthelmintic	Adult male, prostate cancer patient trial, aged 60-84	[28]	https://www.fda.gov/media/96352/download
Nitazoxanide	0.05	Vero E6 cells (ATCC-1586)	Wuhan/WIV04/2020	0.1-100	qRT-PCR/ NP expression, immunofluorescence	500 mg BID	Treatment of diarrhoea caused by	Healthy male volunteers, aged 25 - 45	[27]	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-497_21-

							Giardia lamblia			498s001 Alinia.cfm
Omeprazole	0.002	VeroE6 (ATCC CRL-1586)	BavPat1	0.6µM to 40µM	RT-PCR	40 mg QD	Gastric Ulcer	Adult, female caucasians, mean age 51	[26]	Discontinued
Opipramol	0.002	VeroE6 (ATCC CRL-1586)	BavPat1	0.6µM to 40µM	RT-PCR	100 mg TID	Somatoform disorders and generalised anxiety disorders	Adult healthy volunteers, aged 22 - 32	[26]	http://mri.cts-mrp.eu/download/PL_H_0126_001_FinalSPC.pdf
Oxprenolol	0.002	VeroE6 (ATCC CRL-1586)	BavPat1	0.6µM to 40µM	RT-PCR	320 mg BID	Hypertension and angina pectoris	Healthy Volunteers	[26]	Discontinued
Penciclovir	0.05	Vero E6 cells (ATCC-1586)	Wuhan/WIV04/2019	1-1000	qRT-PCR/ NP expression, immunofluorescence	500 mg TID	Herpes zoster	Healthy Volunteers	[27]	https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/020363s026lbl.pdf
Promethazine	0.01	Vero E6 cells	WA-1 strain - BEI #NR-52292	0.4- 50 uM	plaque assay / TCID50/ qRT-PCR	25mg BID	Motion Sickness	Healthy volunteers	[23]	https://bnf.nice.org.uk/drug/promethazine-hydrochloride.html
Remdesivir 1	0.05	Vero E6 cells (ATCC-1586)	Wuhan/WIV04/2022	0.1-100uM	qRT-PCR/ NP expression, immunofluorescence	200 mg IV loading dose, then 100 mg IV daily for 5-10 days	covid-19	Healthy Volunteers	[27]	https://www.accessdata.fda.gov/scripts/opdlisting/oodp/detailedindex.cfm?cfgridkey=490515
Remdesivir 2	0.002	VeroE6 (ATCC CRL-1586)	BavPat1	0.6µM to 40µM	RT-PCR	200mg IV loading dose, then 100 mg IV daily for 5-10 days	covid-19	Healthy Volunteers	[31]	https://www.accessdata.fda.gov/scripts/opdlisting/oodp/detailedindex.cfm?cfgridkey=490515
Remdesivir 3	0.05	Vero cells (ATCC CCL-81)	SARS-CoV-2 (βCoV/KOR/KCD C03/2020)	0.05–50 µM	CPE	200 mg IV loading dose, then 100 mg IV daily for 5-10 days	covid-19	Healthy Volunteers	[28]	https://www.accessdata.fda.gov/scripts/opdlisting/oodp/detailedindex.cfm?cfgridkey=490515
Remdesivir 4	0.0125	Vero cells (ATCC CCL-81)	SARS-CoV-2 (βCoV/KOR/KCD C03/2019)	0.05–50 µM	Immunofluorescence	200 mg IV loading dose, then 100 mg IV	covid-19	Healthy Volunteers	[28]	https://www.accessdata.fda.gov/scripts/opdlisting/oodp/detailedindex.cfm?cfgridkey=490515

						daily for 5-10 days				
Ribavirin	0.05	Vero E6 cells (ATCC-1586)	Wuhan/WIV04/2022	1-1000	qRT-PCR/ NP expression, immunofluorescence	1200mg OD	HCV	HCV+ patients	[27]	https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021511s023lbl.pdf
Ritonavir	0.01	VeroE6/TMP RSS2	No info	0.01-1000 uM	RT-PCR	600mg BID	HIV	HIV+ adults	[31]	https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021511s023lbl.pdf
Saquinavir	0.01	VeroE6/TMP RSS2	No info	0.01-1000 uM	RT-PCR	1000/100 mg BID (with ritonavir)	HIV	HIV+ males, 83% white, mean age 33	[31]	https://www.ema.europa.eu/en/documents/variation-report/invasive-h-c-113-x-43-epar-assessment-report-extension_en.pdf https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020628s43-021785s19lbl.pdf
Sulfadoxine	0.002	VeroE6 (ATCC CRL-1586)	BavPat1	0.6µM to 40µM	RT-PCR	Sulfadoxine/pyrimethamine FDC (1500/75 mg)	Malaria	Women post-partum	[26]	https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/18557s1r015_fansidar_lbl.pdf
Tamoxifen	0.01	Vero E6 cells	WA-1 strain - BEI #NR-52293	0.4- 50 uM	plaque assay / TCID50/ qRT-PCR	20mg BID	Metastatic breast cancer	Breast Cancer Patients	[23]	https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/17970s053lbl.pdf
Tipranavir	0.01	VeroE6/TMP RSS2	No info	0.01-1000 uM	RT-PCR	500/200 mg BID (with ritonavir)	HIV	Healthy Male Volunteers, mainly white, age 21 - 58	[31]	https://www.ema.europa.eu/en/documents/product-uct-information/apitvus-epar-product-information_en.pdf
Toremifene 1	0.05	Vero E6 cells (ATCC-1586)	Wuhan/WIV04/2023	1-1000	qRT-PCR/ NP expression, immunofluorescence	60mg OD	Metastatic breast cancer	70 patients with Breast cancer	[27]	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021807s005lbl.pdf
Toremifene 2	0.01	Vero E6 cells	WA-1 strain - BEI #NR-52294	0.4- 50 uM	plaque assay / TCID50/ qRT-PCR	60mg OD	Metastatic breast cancer	70 patients with Breast cancer	[23]	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021807s005lbl.pdf

Umifenovir	0.002	VeroE6 (ATCC CRL-1586)	BavPat1	0.6µM to 40µM	RT-PCR	200 mg TID	Prophylaxis/ treatment of influenza in Russia and China	Healthy Chinese subjects	[26]	Not approved by FDA for influenza
------------	-------	---------------------------	---------	------------------	--------	------------	---	--------------------------------	------	--------------------------------------

Table 2. Summary of the top leads identified

Drug	C _{max} :EC ₅₀	C _{max} :EC ₉₀	Approval	Indications	Route of administration	Dosage	Ref
Atazanavir & Ritonavir REYATAZ® (Bristol-Myers Squibb)	3.643	0.728	EMA FDA	HIV-1	Oral	300/100 mg	[99, 100]
Anidulafungin Eraxis®/Ecalta® (Pfizer)	1.323	1.192	EMA FDA	Invasive fungal infections	Intravenous Infusion	200 mg QD + 100 mg QD	[101]
Chloroquine Aralen® (Sanofi Aventis)	2.318	1.261	FDA	Malaria Extraintestinal Amebiasis	Oral	1500mg	[102]
Eltrombopag Promacta® /Revolade® (Novartis)	3.416	2.029	EMA FDA	Primary immune thrombocytopenia Acquired severe aplastic anaemia	Oral	75mg QD	[103]
Favipiravir Avigan® (Fujifilm Toyama Chemical Co)	6.326	2.469	PMDA - Japan	Influenza	Oral	600mg BID	[104]
Hydroxychloroquine Plaquenil®	3.598	0.101	EMA FDA	Malaria	Oral	400mg	[105]

(Sanofi Aventis)							
Indomethacin							
Indocin®	5.366	-	EMA FDA	Rheumatoid arthritis	Oral	50mg TID	[106]
(Merck & Co)							
Lopinavir & Ritonavir							
Kaletra®	2.660 / 1.671	1.630 / 1.240	EMA FDA	HIV-1	Oral	400/100mg BID	[107]
(AbbVie)							
Mefloquine							
Lariam®	1.350	1.284	EMA FDA	Malaria	Oral	250mg	[108]
(Roche)							
Merimepodib							
(Vertex Pharmaceuticals)	1.629	0.638	Not clinically approved	HCV	Oral	300mg TID	[109]
Nelfinavir							
VIRACEPT®	5.849 / 2.287	3.755	EMA FDA	HIV-1	Oral	1250mg BID	[110]
(Roche)							
Niclosamide							
Yomesan®	8.286	4.936	EMA FDA	Infestation with tapeworms	Oral	2000mg	[111]
(Bayer)							
Nitazoxanide							
Alinia®	13.823	6.315	FDA	Diarrhoea caused by Giardia lamblia or Cryptosporidium parvum	Oral	1000 – 2000mg BID	[112]
(Romark Pharmaceuticals)							
Remdesivir							
(Gilead)	5.603 / 2.614	3.755 / 1.712	*Not clinically approved	Ebola	Intravenous	200mg + 100mg	[27]
Ritonavir	1.800		EMA	HIV-1	Oral	600mg	[113]

Norvir® (AbbVie)			FDA				
Sulfadoxine & pyrimethamine Fansidar® (Roche)	6.577		FDA - discontinued	Malaria	Oral	1500/75mg	[114]
Tipranavir & Ritonavir Aptivus® (Boehringer Ingelheim Pharmaceuticals, Inc.)	9.647	6.559	EMA FDA	HIV-1	Oral	500/200mg BID	[115]

*compassionate use programme